Brief: Pharma Mar Receives Positive Opinion From EMA Recommending Approval Of Zepzelca With Atezolizumab

Roche Holding AG

27/03/2026 11:49

March 27 (Reuters) - Pharma Mar SA PHMR.MC:

RECEIVES POSITIVE OPINION FROM THE EMA'S CHMP RECOMMENDING APPROVAL OF ZEPZELCA® (LURBINECTEDIN) IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ®) FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

RECOMMENDATION IS BASED ON THE RESULTS OF THE IMFORTE PHASE 3 TRIAL

LURBINECTEDIN HAS ALSO RECEIVED POSITIVE OPINION FOR DESIGNATION AS ORPHAN DRUG IN SMALL CELL LUNG CANCER

PHASE 3 IMFORTE TRIAL, SPONSORED BY ROCHE IN COLLABORATION WITH JAZZ PHARMACEUTICALS

Source text

Further company coverage: PHMR.MC

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))